bisphosphonate การใช้

• Bisphosphonate molecules preferentially " stick " to calcium and bind to it.
• This is the most widely prescribed bisphosphonate medicine in the United States.
• There is no known prevention for bisphosphonate-associated osteonecrosis of the jaw.
• Etidronate is a bisphosphonate and can reduce the formation of calcium hydroxyapatite crystals.
• Three meta analyses have evaluated whether bisphosphonate use is associated with an increased risk of esophageal cancer.
• The latter is found primarily in post-menopausal women given bisphosphonate drugs, usually against osteoporosis.
• Finally, osteoclast inhibition by the bisphosphonate alendronate has correlated with decreased HSCs and bone marrow engraftment.
• FPPS is the target of bisphosphonate drugs such as Fosamax ( alendronate ) and Actonel ( risedronate ).
• In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
• Current treatment standards include the starting of a bisphosphonate to reduce future fracture risk by up to 50 %.
• Another bisphosphonate, pamidronate, already is given intravenously to women whose breast cancer has spread to their bone marrow.
• Use of bisphosphonate such as zoledronate or ibandronate is currently being investigated, but definite recommendations are not yet available.
• This drug, called a bisphosphonate, shows a remarkable 50 percent reduction in spine and hip fractures after three years.
• Recent studies have reported bisphosphonate use ( specifically zoledronate and alendronate ) as a risk factor for atrial fibrillation in women.
• This type of bisphosphonate has overall more negative effects than the nitrogen containing group, and is prescribed far less often.
• Bisphosphonate drugs are commonly prescribed for bone diseases including Paget s disease, osteolytic metastases, and post-menopausal osteoporosis.
• In contrast, safety studies sponsored by the manufacturer reported bisphosphonate-associated osteonecrosis of the jaw rates that were much lower.
• After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.
• Half the patients received daily oral doses of the bisphosphonate drug clodronate, which has not yet been approved for use in the United States.
• In 1998, a clinical trial demonstrated the effectiveness of intravenous pamidronate, a bisphosphonate which had previously been used in adults to treat osteoporosis.